News About: Pharm. Industry
LG Life Sciences set its sight on OTC drug market
Following its intention to acquire Coca-Cola Korea Bottling Company, LG Life Sciences plans to venture into the domestic over-the-counter (OTC) drug market, said a top official on July 26.
Its intention to step int...
Stock prices of pharmaceutical industries on ever rising trend.
The stock prices of pharmaceutical industries showed ever rising trends amid current hot general bull's markets as a leading stake group in the era of KOSPI 2000s after clearly running out from so far isolated stock m...
Dong-A reported 20% up of operating income at 2Q of 2007.
Dong-A announced on July 27 that the operating income for the 2nd quarter of this year generated 19,142 million won, 62.4% and 20% up from the previous quarter and the same period last year respectively.
The comp...
SK Chemicals erectile dysfunction drug receives marketing Approval in KoreaSK Chemicals announced that it has recently received marketing approval from the Korean Food and Drug Administration for mirodenafil, a new phosphodiesterase type 5 (PDE5) inhib...
|
Dongwha and Samsung on big marketing wars on Whalmyungsoo.
A big market combating bout seems to be struck between Dongwha and Samsung with "Gas whalmyungsoo" and "Gas-myungsoo" through the TV CF.
Two companies tried to refresh their old image of Whalmyungsoo by displaying ...
GSK to launch once every 3 month injectable drug for osteoporosis.
GSK Korea announced to launch Bonviva (ibandronate), an anti-osteoporosis therapy for menopause women, once every 3 month injectable administration via intra-vein.
Bonviva is a class of the biphosphonate drugs with...
Novartis's Tasigna receives first approval in Switzerland
Novartis's cancer treatment Tasigna has received approval in Switzerland, its first certification worldwide.
Switzerland is the first country to approve the drug, which offers a cancer therapy for patients with a f...
KFDA orders sales suspension for Novartis' famvir cream
The government said on July 25 that it banned the sales of Novartis Korea's Famvir (famciclovir) and Dongyang Pharm's cimetiidne and famotidine for six months on grounds of their failure to submit related documents fo...
Many anti-obesity drugs on hot market competition.
A serial market launching of local generic drugs for anti-obesity therapy such as Slimmer and NVU raised a hot market competition, and the market success of which seems to be largely depended on its ex-manufacturers p...
Hanmi to sell Slimmer to Australia.
Hanmi has agreed to supply Slimmer to Australia, which will be a good stepping stone for an entry of the European markets.
Hanmi announced on July 24 that the company made a distribution agreement with iNova in Aus...
